MAJIC : A Phase II Study of Ruxolitinib (INCB424) in Patients with High Risk Polycythaemia Vera or Essential Thrombocythaemia Resistant to or Intolerant of Standard Therapy

  • Craddock, Charles (Principal Investigator)

Project Details

Short titleMAJIC : A Phase II Study of Ruxolitinib (INCB424) in Patients with High Risk Polycythaemia Vera or Essential Thrombocythaemia Resistant to or Intolerant of Standard Therapy
StatusActive
Effective start/end date23/05/12 → 31/12/23

Funding

  • NOVARTIS PHARMACEUTICALS UK LTD